DexCom, Inc. — 7.1/10
BUYNASDAQ: DXCM | High-quality, recovering CGM franchise. Re-accelerating revenue off 2024 trough. Strongly growing FCF. Declining share count. Expanding profitability below gross line. Forward valuation below med-tech peers. Dense near-term catalyst calendar (T2 non-insulin expansion, CMS coverage, Stelo OTC). BUT DexCom is the #2 player (not the leader) in a duopoly where Abbott is gaining US share. Brand-new CEO (Jan 2026) — management track record gate fails. Well-liked Strong Buy name with limited contrarian edge. Quality gate: PARTIAL PASS (1 NO — management).
Financial Trends
8/10
Re-accelerating revenue | FCF growing strongly
Thematic
7/10
CGM duopoly #2 | Abbott gaining share
Management
6/10
New CEO Jan 2026 | Gate NO
Concerns & Risks
8/10
Below-peer valuation | Dense catalysts
Company overview
DexCom is the second-largest global continuous glucose monitoring (CGM) company, operating in a duopoly with Abbott that together controls approximately 91% of the CGM market (Abbott ~56%, DexCom ~35%). The company designs and manufactures wearable CGM sensors that continuously track glucose levels, primarily for people with diabetes. The penetration runway is massive: Type 1 CGM penetration is approximately 30%, Type 2 insulin-dependent penetration is below 5%, and Type 2 non-insulin penetration is below 1%.
Revenue is re-accelerating off the 2024 trough caused by the Q2 2024 guide-down, a material credibility event where management cut guidance by approximately $250M due to a botched salesforce expansion. FCF is growing strongly and the share count is declining. Profitability is expanding below the gross margin line. Forward valuation sits below med-tech peers despite a dense near-term catalyst calendar that includes T2 non-insulin expansion, CMS coverage, and Stelo OTC scaling.
The key offset: DexCom is the #2 player, not the leader, in a duopoly where Abbott is gaining US share. A brand-new CEO took the helm in January 2026, meaning the management track record gate fails. The bull case is well-understood by the Street (Strong Buy consensus), limiting contrarian edge.
| CEO | New (Jan 2026) | Market Cap | $26.5B |
| Revenue Trajectory | Re-accelerating off 2024 trough | FCF / Capital Return | Strongly growing FCF, declining share count |
| Competitive Position | #2 in CGM duopoly (Abbott is #1 and gaining share) | Catalyst Calendar | Dense: T2 non-insulin, CMS, Stelo OTC |
| Fiscal Year End | December 31 | Quality Gate | PARTIAL PASS (1 NO: management) |
Score breakdown
Financial TrendsWeight: 25%
Re-accelerating revenue off the 2024 trough with strongly growing FCF that has crossed the $1B threshold. Declining share count and expanding operating margins below the gross line. Guided 11-13% revenue growth for 2026 with multiple upside drivers not embedded in guidance (Medicare T2NI, G7 15-day, Stelo scaling). Docked from higher because gross margin recovery remains incomplete and growth is rebasing to structurally lower than pre-shock 20%+.
Thematic ExposureWeight: 35%
CGM duopoly with Abbott (91% combined share) provides structural pricing power and barriers to entry. Massive penetration runway: Type 2 insulin <5%, Type 2 non-insulin <1%. TAM expanding from $13.3B to $31B+ by 2031. GLP-1 is a tailwind (4x CGM adoption among users). Capped at 7 because DexCom is the #2 player and Abbott is gaining share, the company is 100% single-category, and key catalysts (Medicare T2NI, Stelo scaling) remain aspirational.
Management QualityWeight: 20%
Gate NO. Brand-new CEO (Jan 2026) with no established track record as a public company CEO. The Q2 2024 guide-down (~$250M self-inflicted cut from botched salesforce expansion) was a top-tier credibility event that six quarters of recovery cannot fully offset. Capital allocation has been strong ($1.2B convert settled, $750M+ buybacks), and 8/10 post-crisis promises have been met, but the management gate fails on track record.
Investor SentimentWeight: 5%
Well-liked Strong Buy consensus name with limited contrarian edge. The bull case (CGM penetration, Medicare T2NI, GLP-1 tailwind) is thoroughly understood by the Street. Analyst price targets imply significant upside, but buy-side is clearly not following sell-side. The stock exhibits a persistent beat-and-sell pattern. Not deeply negative enough to be a contrarian opportunity, not positive enough to provide momentum.
Concerns & RisksWeight: 15%
Forward valuation below med-tech peers despite re-accelerating growth. Dense near-term catalyst calendar: T2 non-insulin expansion, CMS coverage decision, Stelo OTC scaling, G7 15-day international. Low China/tariff exposure. Offset partially by Abbott competitive pressure (gaining share), FDA warning letter overhang, and execution risk from simultaneous product launches under a new CEO.
| Dimension | Score | Weight | Weighted |
|---|
| Financial Trends | 8 | 25% | 2.00 |
| Thematic Exposure | 7 | 35% | 2.45 |
| Management Quality | 6 | 20% | 1.20 |
| Investor Sentiment | 5 | 5% | 0.25 |
| Concerns & Risks | 8 | 15% | 1.20 |
| Composite | | 100% | 7.10 → 7.1 |
Summary thesis
DXCM scores 7.1/10, reflecting a recovering, high-quality CGM franchise with strong financial trends (8/10) and a favorable risk profile (8/10 — below-peer valuation, dense catalysts, low China risk). The score is held in the high-6s by three factors: (1) a new CEO with no established track record, causing the management gate to fail (gate NO), (2) being the #2 player in a duopoly where Abbott is gaining share, and (3) a well-understood bull case with limited contrarian edge.
Quality gate: PARTIAL PASS (1 NO). Oligopoly YES — Abbott + DexCom control 91% of CGM. Positive/growing FCF YES — FCF crossed $1B, growing strongly with declining share count. Management track record NO — brand-new CEO (Jan 2026) with no track record as a public company CEO, compounded by the Q2 2024 guide-down credibility event.
Data sourced from
Daloopa (company_id: 6704). Analysis date: 2026-06-25.